Alpha Cognition (NASDAQ:ACOG) Price Target Raised to $20.00

Alpha Cognition (NASDAQ:ACOG) had its target price increased by HC Wainwright from $18.00 to $20.00 in a research note published on Monday morning, Marketbeat reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Alpha Cognition’s Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.33) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at $0.01 EPS and FY2027 earnings at ($0.31) EPS.

A number of other equities research analysts also recently issued reports on the stock. Wall Street Zen raised shares of Alpha Cognition from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Maxim Group started coverage on Alpha Cognition in a report on Friday, May 29th. They issued a “buy” rating and a $12.00 target price on the stock. Craig Hallum reiterated a “buy” rating and set a $17.00 target price on shares of Alpha Cognition in a research report on Friday, August 14th. Finally, Raymond James Financial initiated coverage on Alpha Cognition in a research report on Friday, July 10th. They set an “outperform” rating and a $20.00 target price on the stock. Five research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $17.25.

Alpha Cognition Trading Up 3.7%

Shares of NASDAQ ACOG opened at $8.89 on Monday. The firm has a 50 day moving average of $7.91 and a 200 day moving average of $6.59. The firm has a market capitalization of $193.62 million, a price-to-earnings ratio of -8.08 and a beta of 2.31. Alpha Cognition has a 12-month low of $4.50 and a 12-month high of $10.00.

Alpha Cognition (NASDAQ:ACOG) last announced its earnings results on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.01). Alpha Cognition had a negative net margin of 153.61% and a negative return on equity of 54.60%. The business had revenue of $6.00 million for the quarter, compared to analysts’ expectations of $4.38 million. Sell-side analysts predict that Alpha Cognition will post -1.42 EPS for the current year.

Institutional Investors Weigh In On Alpha Cognition

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ACOG. Geode Capital Management LLC bought a new position in shares of Alpha Cognition in the second quarter worth approximately $112,000. Massar Capital Management LP purchased a new stake in shares of Alpha Cognition in the second quarter worth $116,000. Two Sigma Investments LP bought a new stake in shares of Alpha Cognition during the 3rd quarter valued at $148,000. Connective Capital Management LLC bought a new stake in shares of Alpha Cognition during the 3rd quarter valued at $312,000. Finally, ACT Capital Management LLC bought a new stake in shares of Alpha Cognition during the 4th quarter valued at $335,000.

Key Alpha Cognition News

Here are the key news stories impacting Alpha Cognition this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $20 price target, well above recent trading levels. The firm also raised its Q1 2027 EPS estimate to a loss of $0.12 from $0.19 and lifted its FY2027 forecast to a loss of $0.31 from $0.32.
• Positive Sentiment: The analyst expects Alpha Cognition to reach approximately breakeven in Q4 2027, revising the forecast to $0.01 EPS from a $0.01 loss. This suggests improving longer-term operating trends, although profitability remains distant.
• Neutral Sentiment: HC Wainwright’s updated forecasts remain broadly aligned with the company’s loss-making profile: losses of $1.33 per share in FY2026 and $0.31 per share in FY2027, compared with the current-year consensus estimate of a $1.34 loss.
• Negative Sentiment: The firm reduced its FY2026 EPS estimate to a loss of $1.33 from $1.08 and cut Q3 2026 EPS expectations to a loss of $0.33 from $0.20. Q4 2026 was also lowered to a $0.25 loss from $0.20.
• Negative Sentiment: Q2 2027 and Q3 2027 estimates were reduced to losses of $0.13 and $0.07 per share, respectively. These revisions indicate that near-term expenses and cash-burn concerns may be greater than previously expected.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.